Marinomed Biotech AG, a globally active biopharmaceutical company based in Vienna, achieved a number of important milestones in the first three quarters of 2019. Following the completion of the successful phase III study for the new allergy drug Budesolv, the company has prepared for the approval and commercialization of the industry leading product.
Born2Invest brings you new scientific breakthroughs from all over the world. Our companion app allows you to get finance headlines from industries like banking, cannabis, biotech, and much more. Our software distills news into 500 characters or less so that no matter where you are or how busy your schedule is, you are always updated.
“Our goal is to make Budesolv available to as many allergy patients as possible, and as quickly as possible. In November 2019, more detailed Phase III clinical data was presented for the first time at the prestigious ACAAI Congress in Houston, USA. These data demonstrate the effectiveness of our innovative Marinosolv® platform. We are confident that we will be able to successfully use the technology in further projects,” said Dr. Andreas Grassauer, CEO of Marinomed.
With the products of the Carragelose® segment, the first causative treatment against colds and flu, Marinomed achieved slight sales growth of $3.63 million (€3.30 million) in the first nine months of 2019 (1-9/2018: $3.55 million (€3.23 million)).
In order to achieve its long-term growth targets, Marinomed focused on investments in research and development in the first three quarters of 2019. At $3.51 million (€3.19 million), these were significantly higher than in the same period of the previous year (1-9/2018: $2.32 million (€2.11 million)). As planned, the operating result (EBIT) was negative in the reporting period at -$5.81 million (-€5.28 million), reflecting the high R&D expenses and, in particular, the one-off costs in connection with the IPO (1-9/2018: -$3.40 million (-€3.09 million)).
The losses for the first three quarters of 2019 amounted to -$6.77 million (-€6.15 million), compared with -$4.19 million (-€3.81 million) in the same period of the previous year. Total assets increased from $5.79 million (€5.26 million) as of December 31, 2018, to $17.37 million (€15.77 million) as of September 30, 2019. Cash equivalents increased to $11.39 million (€10.34 million) in the first nine months of 2019 (12/2018: $1.89 million (€1.72 million)).
Marinomed has an extremely solid capital base to finance its high research and development expenses. That was further strengthened by the European Investment Bank’s loan commitment of up to $16.52 million (€15 million).
In October 2019, Marinomed utilized the first tranche of the $4.40 million (€4 million) loan and is planning to use it primarily for further research in the Marinosolv® segment. Marinosolv® offers various application possibilities, as a large number of existing drugs could be optimized by better dissolution of the active ingredients.
Marinomed also plans further investments in the Carragelose® segment – in clinical studies, in optimizing production and in continuing the approval process for Carravin, a combination of Carragelose® and the decongestant active ingredient xylometazoline.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in FinanzNachrichten, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
Buffett Made This One Big Mistake. Don’t Let Yourself Do the Same
When an investment opportunity like AR and VR comes along, it can be hard knowing when to jump. Even if...
Bank of America Sees Bitcoin as an Opportunity for El Salvador
September 7th, 2021 is the date set for the introduction of Bitcoin as the official currency in El Salvador. BTC...
Spanish Biotech Companies’ Profits Fall 28% in the First Half of the Year
Grifols, which specializes in the production of plasma derivatives, achieved a profit of $317.2 million (€266.8 million) in the first...
The Economic Situation in Morocco: Domestic Demand Continues to Recover
Domestic demand in Morocco continued to recover in Q2-2021. According to the HCP, household consumption has, in fact, strengthened by...
Soybeans Market Closed Lower on Friday
Soybeans and the products were lower on Friday. Soybeans closed the week a little higher while the products were narrowly...
Business7 days ago
The Metaverse Is the Way of the Future, and Facebook Just Confirmed It
Cannabis6 days ago
Colombia Now a Major Player in Industrial Cannabis Production
Business5 days ago
Forget Facebook (NASDAQ: FB) and Apple (NASDAQ: AAPL): Virtual Reality (VR) and Augmented Reality (AR) Investors Should Snap Up XRApplied (CSE: XRA) Instead
Crowdfunding6 days ago
Eltif ALICrowd Invests €600,000 in the Equity Crowdfunding Campaign of Orapesce